ERBB2 and breast carcinoma: Thus, these cells will permit a comprehensive approach to evaluating potential drugs targeting PIK3CA/PTEN–wild‐type, HER2‐positive, trastuzumab‐resistant breast cancer, which comprises a large proportion of the trastuzumab‐resistant breast cancer population.